Nektar Therapeutics (NKTR)

Nektar Therapeutics is trading at $38.87, down 0.79% on the session. The 50 day average sits at $55.69 and the 200 day at $65.01, which puts the stock in a downtrend. RSI is at 34.7, which reads as weak, and MACD is bullish crossover. Volume is below average.

The nearest support is around $38.45 with resistance near $40.35, so that band frames the current range. Average daily movement is roughly $2.31, or about 5.9% of the share price, which is what any stop placement has to allow for. The overall health score of 30 out of 100 combines a trend score of 0, momentum of 44 and a risk score of 58.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.